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Stimuli-responsive lipid-based magnetic
nanovectors increase apoptosis in glioblastoma
cells through synergic intracellular hyperthermia
and chemotherapy†
Christos Tapeinos, *‡a Attilio Marino,*‡a Matteo Battaglini,a,b Simone Migliorin,c
Rosaria Brescia, d Alice Scarpellini,d César De Julián Fernández, e
Mirko Prato, f Filippo Dragog and Gianni Ciofani *a,c
In this study, taking into consideration the limitations of current treatments of glioblastoma multiforme,
we fabricated a biomimetic lipid-based magnetic nanovector with a good loading capacity and a sus-
tained release profile of the encapsulated chemotherapeutic drug, temozolomide. These nanostructures
demonstrated an enhanced release after exposure to an alternating magnetic field, and a complete
release of the encapsulated drug after the synergic effect of low pH (4.5), increased concentration of
hydrogen peroxide (50 μM), and increased temperature due to the applied magnetic field. In addition,
these nanovectors presented excellent specific absorption rate values (up to 1345 W g−1) considering the
size of the magnetic component, rendering them suitable as potential hyperthermia agents. The pre-
sented nanovectors were progressively internalized in U-87 MG cells and in their acidic compartments
(i.e., lysosomes and late endosomes) without affecting the viability of the cells, and their ability to cross
the blood–brain barrier was preliminarily investigated using an in vitro brain endothelial cell-model. When
stimulated with alternating magnetic fields (20 mT, 750 kHz), the nanovectors demonstrated their ability
to induce mild hyperthermia (43 °C) and strong anticancer effects against U-87 MG cells (scarce survival
of cells characterized by low proliferation rates and high apoptosis levels). The optimal anticancer effects
resulted from the synergic combination of hyperthermia chronic stimulation and the controlled temozo-
lomide release, highlighting the potential of the proposed drug-loaded lipid magnetic nanovectors for
treatment of glioblastoma multiforme.
Introduction
Glioblastoma multiforme (GBM) is one of the most malignant
brain tumors associated with high percentages of mortality
worldwide and with a 5-year survival rate of less than 10%.1
The reason for the inability to treat this form of cancer lies in
several factors, including its rapid growth, the location and the
pathophysiology of the tumor that in many cases forbid its
surgical resection, and the blood–brain barrier (BBB) that
hinders efficient delivery of various chemotherapeutics to the
malignant tissue.1–3
The contemporary approaches for the treatment of GBM
consist of surgical resection, radiotherapy (the role of which is
controversial), adjuvant or neoadjuvant chemotherapy using
temozolomide, and, finally, hyperthermia using superpara-
magnetic iron oxide nanoparticles.4,5 Although in certain
cases the median overall survival of patients increases, in the
majority of the patients these treatments have a more palliative
than curative role.
The combination of surgical resection and chemotherapy is
used as a gold standard for many forms of cancer (e.g., breast,
prostate, pancreatic, etc.), but, unfortunately, not all patients
are able to undergo this combinatory therapy, leading to an
unmet clinical need. In addition, in many cases where the
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patient can undergo this combinatory treatment, the side-
effects of the administered chemotherapeutics negatively affect
the quality of life of the patient, resulting in a controversy con-
cerning their use. Radiotherapy is another form of treatment
which is also used in combination with chemotherapy, in
cases where surgery cannot be performed, but this combi-
nation is not only less effective than chemotherapy and
surgery, but also results in an increased number of side
effects, causing the same controversies as chemotherapy.
One of the reasons for the low success rates in increasing
patient survival stems from the low efficacy of the used chemo-
therapeutics due to various causes, including the fast
reticuloendothelial system clearance, the non-controllable bio-
distribution, and the inability to cross the BBB.1,6,7
In order to overcome the limitations that the current che-
motherapeutics like temozolomide (TMZ) present, these
chemical substances are encapsulated inside delivery vehicles
aiming at improving their efficacy. These delivery vehicles are
made of a variety of different materials like synthetic and/or
natural polymers and lipids, and can be in the form of micro-
spheres, nanospheres, nanoparticles, micelles, nanorods,
nanotubes, hydrogels, and others.8–12 Each one of these
systems presents its own advantages and disadvantages and
depending on the application, a different type is used every time.
These vectors can be also designed in a way to alter their
physicochemical properties under a specific stimulus, which
can be either physical, chemical, biological, or any combi-
nation of them. This ability enhances the efficacy of the syn-
thesized vehicles, since, by controlling their properties, drug
release, increase of temperature, or their guidance in the can-
cerous tissue can be achieved in a controlled manner.8,11,13
These delivery vehicles (or nanovectors) demonstrate a bio-
mimetic character with increased biocompatibility and low
immunogenicity, which allows them, as mentioned above, to
effectively deliver in a controlled way various therapeutic sub-
stances. Their small size and their ability to be coated with a
variety of natural or synthetic materials allow them to increase
their circulation time in the blood, and to effectively deliver
the encapsulated therapeutic molecules towards the tissue of
interest. Because of the difficulty that the majority of the used
therapeutic agents face in crossing the BBB, a limited number
of nanovectors can be used for the treatment of GBM and
these nanovectors are composed of various lipids that can be
classified into different types, the most common of which
include solid lipid nanoparticles (SLNs), nanostructured lipid
carriers (NLCs), and liposomes (LS).14 These nanovectors
present an inherent ability to cross the BBB and when properly
functionalized demonstrate an enhanced targeting ability and
a subsequent increased uptake by the endothelial cells of
the BBB, as well as by glioblastoma cells like the U-87 and
U-251 malignant glioma (MG) cells.
During the last few years, and especially after the Food and
Drug Administration (FDA) approved the use of superpara-
magnetic iron oxide nanoparticles (SPIONs) as magnetic reso-
nance imaging contrast agents as well as for the treatment of
brain cancer using hyperthermia, many researchers have pre-
sented studies where lipid-based delivery vehicles encapsulat-
ing magnetite nanoparticles (Fe3O4) and/or chemotherapeutic
agents were used for the treatment of this and other types of
cancer.11,15–17
During hyperthermia, inorganic nanoparticles like magne-
tite or maghemite (γ-Fe2O3), coated with synthetic materials
like polymers or with natural-derived materials like collagen,
albumin, lipids and others, are subjected to an alternating
magnetic field (AMF) of a specific frequency, which forces
them to increase the temperature of their surrounding
environment due to dissipative losses (Néelian, Brownian, and
hysteresis).18
It should be noted that, although magnetic hyperthermia is
not a novel concept for the treatment of various types of
cancer, to date its use has been either experimental or it has
been restricted only to patients in a small number of clinical
trials, and this is mainly because the use of hyperthermia
alone is not enough to cure GBM.
Taking into consideration all the above limitations concern-
ing the use of smart drug delivery systems, we hypothesized
that the combination of magnetic hyperthermia, using SPIONs
encapsulated in a lipid-based nanovector, and the sustained
release of TMZ, a golden standard for GBM, will increase the
therapeutic efficacy of the designed nanovector, resulting into
increased apoptosis and in the subsequent death of glioblas-
toma cells. A simple one-pot procedure was used to synthesize
the composite nanovectors, which were morphologically, physico-
chemically, and magnetically characterized. The designed
lipid-based magnetic nanovectors (LMNVs) demonstrated high
stability in water as well as in media that simulated the body
fluids and a sustained release profile for a period of seven
days. The LMNVs succeeded in increasing the temperature of
the solution from 37 °C to 43 °C in just a few minutes with
better hyperthermia properties (specific absorption rate and
intrinsic loss power) than bare SPIONs. Chronic stimulation
under an AMF of the U-87 MG cell line, in the presence of just
400 μg cm−2 of LMNVs, led to an increase in apoptosis after
4 days by 50%, and to a reduction of proliferation by 80%.
Results and discussion
Synthesis procedure
The lipid-based magnetic nanovectors used in this study were
fabricated following a combination of the hot ultra-sonication
and high pressure homogenization (HPH) methods. Ultra-soni-
cation resulted in the formation of a nano-emulsion which
was further homogenized using the HPH. Dynamic light scat-
tering studies on LMNVs fabricated only by the hot ultra-soni-
cation method (results not presented here) demonstrated that
the nanovectors had a similar hydrodynamic diameter but
increased polydispersity, rendering mandatory the use of HPH
in order to achieve a monodisperse population. The tempera-
ture for the melting and subsequent homogenization of the
lipid mixture was chosen to be 70 °C, which is higher than the
melting temperature (57–65 °C) of the primary lipid (glycerol
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monostearate, GMS), in order to have a homogeneous dis-
persion of the secondary lipids as well as of the SPIONs in the
main lipid matrix. In addition, this temperature is close to the
boiling point of ethanol, which is used as a dispersant for the
SPIONs, allowing its complete evaporation and the formation
of a homogeneous liquid film. The choice of Tween® 80 as a
stabilizer was made based on the literature findings where it is
demonstrated that Tween® 80 enhances the delivery of nano-
particles across the BBB due to its ability to adsorb a variety of
lipoproteins such as apo-lipoprotein A, E, and others.19,20
Morphological and physicochemical characterization
The LMNVs were firstly characterized using transmission elec-
tron microscopy (TEM) and the results are presented in Fig. 1A
(and in ESI, Fig. S1†). The LMNVs present a spherical shape
and a relatively low polydispersity in the nanometer range.
Their size distribution after analysis with ImageJ (see ESI,
Fig. S1C†) shows that 86% of the nanovectors have a size of
less than 50 nm with only a small number of them exceeding
100 nm. These results are in agreement with dynamic light
scattering as well as with nanoparticle tracking analysis (NTA)
data that are presented below. The magnified image of the
unstained LMNV presented in Fig. 1A2 demonstrates the
homogeneous dispersion of the SPIONs inside the lipid matrix
of the nanovectors, which was also proved by the electron dis-
persive X-ray (EDS) mapping of iron (Fe) and oxygen (O) in
Fig. 1A3 and A4, respectively. In order to quantify the amount
of each element in the fabricated LMNVs, we performed an
Fig. 1 Morphological and physicochemical characterization of LMNVs: (A1) high-angle annular dark field-scanning transmission electron
microscopy (HAADF-STEM) image of LMNVs, (A2) magnified HAADF-STEM image of one unstained LMNV where the distribution of the encapsulated
SPIONs is presented, (A3) and (A4) EDS maps of Fe and O over single LMNV, respectively; (B) XPS graph demonstrating the elements present on the
surface of the LMNVs; (C) FT-IR spectra of plain SPIONs (bottom) and LMNVs (top) showing peaks attributed to the SPIONs (Fe–O), depicted inside
the green rectangular area, and to the lipid components; (D) TGA/DTA graph presenting the weight reduction of the LMNVs during the melting of
the lipids and of the polymeric components of the LMNVs (black curve). The red dashed line represents the derivative weight in which each peak
represents transition temperatures (melting points) attributed to both the lipid matrix and the incorporated PEG; (E) Gaussian distributions of the
hydrodynamic diameter (100 nm) of the LMNVs at various temperatures; (F) correlograms of the LMNVs at various temperatures demonstrating the
stability of the LMNVs; (G) surface charge (about −19 mV) of the fabricated LMNVs at various temperatures.
Paper Nanoscale
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EDS analysis (Fig. S2†) and we calculated the percentage per
weight of each element. The results demonstrate the presence
of C (24.6%), O (35.13%), and Fe (40.14%), proving the exist-
ence of a lipid as well as of an iron-based component.
The surface of LMNVs was characterized using X-ray photo-
electron spectroscopy (XPS) (Fig. 1B) from which it was found
that the percentage of Fe on their surface comprises 0.8% of
the surface elements (C: 81.6%, O: 15%, N: 0.6%, Na: 1.0, Cl:
0.2%, Si: 0.7%). Analysis of the binding energy region between
700 eV and 740 eV, typical of Fe 2p peaks, revealed the pres-
ence of Fe 2p3/2 and Fe 2p1/2 peaks at approximatively 710.4 eV
and 724.1 eV, respectively; importantly, the collected data do
not show the presence of any well-defined satellite peak in the
region between the two XPS peaks. The observed positions,
together with the absence of the satellite peak, are in good
agreement with results reported in a previous study21 on
Fe3O4.
Infra-red spectroscopy was also used as a complementary
technique to verify the presence of SPIONs inside the LMNVs.
The spectra of the SPIONs as well as of the LMNVs are pre-
sented in Fig. 1C. The peaks in the range of 550–600 cm−1 that
are visible both in the spectra of SPIONs (bottom) and of
LMNVs (top) can be attributed to the vibrations between Fe
and O of the encapsulated SPIONs. The peaks at 1100 cm−1
and at 1730 cm−1 that can be seen only in the LMNV spectrum
(Fig. 1C – top) are attributed, respectively, to the C–O and
CvO stretching vibrations of the aliphatic chain of the lipids.
The peaks at 2841 cm−1 and 2914 cm−1 in the LMNVs spec-
trum belong to the C–H stretching vibrations of the aliphatic
chain, while the broad peaks in the range of 3100–3500 cm−1,
which can be seen in both spectra, are attributed to O–H
stretching vibrations.
The total percentage of Fe inside the LMNVs as well as the
amount of SPIONs inside the LMNVs were calculated using
inductively coupled plasma optical emission spectroscopy
(ICP-OES) and thermogravimetric analysis (TGA), respectively.
The ICP-OES results showed that Fe represents 66.8% of the
LMNVs, while thermogravimetric analysis demonstrated
that 88% of the LMNVs are composed of SPIONs.
Thermogravimetric analysis of the LMNVs was carried out in
order to calculate the percentage of encapsulated SPIONs, as
well as to evaluate any structural changes related to tempera-
ture alterations. Fig. 1D depicts both the weight loss and the
differential thermogravimetric curve of the LMNVs. From
these curves, the structural deformation as well as the
decomposition of the lipid and of the polymeric part of the
nanostructure are evident. When the temperature is above
50 °C, a weight loss can be observed, which can be attributed
to water molecules trapped on the surface of the LMNVs
(50–100 °C), as well as due to the decomposition of the GMS,
mPEG-DSPE (methoxy-poly(ethylene glycol)-1,2-distearoyl-sn-
glycero-3-phospho-ethanolamine), and DPPC (1,2-dipalmitoyl-
rac-glycero-3-phosphocholine). This loss is achieved in multiple
steps as can be observed from the differential thermal analysis
graph, where three peaks are presented (Fig. 1D). The first
peak can be attributed to the degradation of the poly(ethylene
glycol) chain derived from mPEG-DSPE, while the second one
can be attributed to the release of energy due to the structural
deformation resulting from the parallel decomposition of all
the lipid components. Finally, the third peak can be attributed
to the degradation of GMS. Above 380 °C, it can be observed
that there is no further weight loss due to the fact that both
the polymeric and the lipid coating have been completely
degraded. The remaining weight can be attributed to the
encapsulated SPIONs and corresponds approximately to 88%
of the initial weight as was mentioned before.
Stability studies
The stability of the LMNVs was studied in media with different
conductivities and ionic strengths, and at different tempera-
tures, in order to assess their behavior under conditions that
simulate the cancerous environment, as well as conditions
that simulate their exposure to hyperthermia treatment (T >
42 °C). In addition, the stability of the LMNVs in relation to
protein corona formation was also assessed by studying their
behavior in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS).
The results presented in Fig. 1E demonstrate that the
LMNVs are stable as the temperature increases from 25 °C to
46 °C, maintaining an average hydrodynamic diameter (Rd) of
106.2 ± 13.0 nm and a polydispersity index (PDI) of 0.206 ±
0.030. The correlograms presented in Fig. 1F demonstrate a
good decay time and a flat line at the end of the curves for all
the samples, proving the absence of sedimentation over time
and over temperature increment, as well as the absence of
aggregation. The average Z-potential value of the LMNVs, at
various temperatures (Fig. 1G), was found to be −19.0 ±
1.3 mV. Although this value is higher than −30 mV, which is
considered the threshold for the colloidal stability of a system,
our fabricated nanovectors demonstrated excellent stability,
both in water and in biologically simulated fluids (DMEM +
10%FBS). This behavior can be attributed to the synergic effect
of the electrostatic repulsion due to the negative surface
charge of the LMNVs, as well as to the steric hindrances due to
the incorporated PEG.
The hydrodynamic diameter values in dynamic light scat-
tering (DLS) are higher compared to the diameters presented
in TEM, and this difference can be attributed to the PEG
segment that creates a layer around the particles, which swells
when inside the liquid dispersant, resulting in increased
values of the hydrodynamic diameter.
After assessing the stability of the LMNVs at different temp-
eratures, we studied their behavior in different dispersants
which more accurately simulate the conditions inside the
human body (see ESI, Fig. S3†). Water was used as a control
since, in our previous measurements, it was used to prove the
temperature-dependent stability of the LMNVs. The other two
dispersants that were used were DMEM and DMEM sup-
plemented with 10% FBS (DMEM + 10%FBS). The hydro-
dynamic diameter graphs (see ESI, Fig. S3† – top) and the cor-
relograms (see ESI, Fig. S3† – bottom) show that the LMNVs
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are stable in water after 1, 6 and 24 h at 37 °C, further proving
their stability for a longer period than 6 h. In these graphs it
can also be observed a significant difference between LMNVs
in DMEM and LMNVs in DMEM + 10%FBS, a difference that
can be attributed to the protein corona formation around the
LMNVs, mostly due to the albumin inside the serum. The
protein corona is evident at all the time points, since the size
distribution of the nanovectors in the DMEM + 10%FBS (blue
curves) is always shifted on the right (higher hydrodynamic
diameters) compared to the LMNVs dispersed in ultrapure
water (black curves). This difference between DMEM + 10%FBS
and water is not evident from the corresponding correlograms,
but the difference between these dispersants and the plain
DMEM is pretty clear. Plain DMEM graphs present always
higher values of hydrodynamic diameter, and this is because
the high ionic strength of the media results in aggregates as it
can be seen from the graphs in ESI, Fig. S3,† where the curves
belonging to the LMNVs dispersed in DMEM (red curves) are
shifted to higher hydrodynamic values and present higher
intensity. This higher intensity can also be observed in the
curves belonging to the LMNVs dispersed in water after 6 and
24 h, suggesting that an aggregation may occur.
In order to further assess the stability of the nanovectors
and to assess the probable creation of aggregates in water as
well as in DMEM and DMEM + 10%FBS, we performed nano-
particle tracking analysis (NTA) in all of the dispersants after
24 h. Using this method we were able to assess the behavior of
the nanovectors in a liquid under flow, observing each particle
separately, since NTA has the ability to record the movement
of each dispersed particle passing through a high resolution
camera with a specific speed. The results that are presented in
ESI, Fig. S4 and Table S1† demonstrate that there is an aggre-
gation of the LMNVs in water after 24 h (see ESI, Fig. S4† –
black curve, and Table S1† – D50 and D90 values) which
cannot be seen in the DLS graphs due to the limitations of the
equipment. From Fig. S4 and Table S1† it can also be seen
that the LMNVs in DMEM and DMEM + 10%FBS have lower
hydrodynamic diameters compared to water, suggesting firstly
that DMEM is not significantly affecting the hydrodynamic
values as noticed by the DLS analysis, probably due to the fact
that the measurement takes place under flow, and secondly
that the LMNVs in DMEM + 10%FBS demonstrate good hydro-
dynamic values that can be attributed probably to the stability
that the protein corona offers to the nanovectors. From these
studies it can be concluded that the LMNVs present a higher
stability in high ionic strength media when these media are
supplemented with proteins like those present in the FBS.
Although the high ionic strength destroys the Stern layer of the
nanovectors in the medium, these nanovectors remain stable
probably due to the electrostatic and/or steric interactions
between the protein layers.22–24
Magnetic characterization
The magnetic properties of the 3 nm SPIONs before and after
their encapsulation in the lipid matrix were studied using a
superconducting quantum interference device (SQUID).
Considering the hysteresis loops measured at room tempera-
ture (Fig. 2A), it has been found that the specific magnetization
of the free SPIONs (62 emu g−1) is almost two times higher than
that of the LMNVs (32 emu g−1), and this difference can be
attributed to the additional mass of the lipid matrix. However,
the analysis of the hysteresis at low fields (Fig. 2B) shows that
the SPIONs are “magnetically” different with respect to the
LMNVs. Free SPIONs have a coercive field of around 10 Oe,
while the LMNVs do not present any coercivity (within the
limits of precision of the instrument). The absence of coerciv-
ity at room temperature is an indication that all the particles
inside the lipid matrix are superparamagnetic. However, the
presence of a weak coercivity in the SPIONs indicates the pres-
ence of a population of blocked particles. In fact the zero-field
cooled and field cooled (ZFC–FC) curves of the SPIONs that are
presented in Fig. 2C not only exhibit a peak at 200 K that
could be correlated with the blocking temperature of the main
population of superparamagnetic particles, but they are also
separated at room temperature, supporting the presence of a
population of blocked particles. In the first instance, the block-
ing temperature is correlated with the particle size of the
SPIONs,25,26 here 3 nm. This size is too small to explain the
blocking temperature of 200 K and even less the presence of
blocked nanoparticles at room temperature. In fact, it is more
reasonable to consider that the blocking process is correlated
to the inter-particle coupling present in the observed aggre-
gates of SPIONs in the pure sample.25,27,28 In the LMNVs these
aggregates of particles were not observed, thus explaining the
full superparamagnetic behavior of the particles at room
temperature.
In order to assess the ability of the LMNVs to be used in
hyperthermia therapy, we studied the increase of temperature
in response to an external AMF at various frequencies. The
results presented in Fig. 2D demonstrate that 5.4 mg ml−1
(66.8% of Fe according to ICP results and 4.8 mg ml−1 of
Fe3O4 according to TGA) of LMNVs can increase the tempera-
ture of the dispersant from 27.5 °C to 46.0 °C in 30 min, while
the increase from 37.0 °C (human body temperature) to 43.0 °C
(mild hyperthermia temperature) can be achieved in a period of
approximately 10 min, demonstrating their potential for in vitro
and in vivo use. Data for stimulation using 2.4 mg ml−1 of
LMNVs are, moreover, provided in the ESI (Fig. S5†).
The effectiveness for the radiofrequency magnetic
hyperthermia is quantified by measuring the specific absorp-
tion rate (SAR) and the intrinsic loss power (ILP). In both cases
the nanoparticles dispersed in the solvent media are exposed
to magnetic fields of different intensities as well as of different
frequencies. The increase in the first moments of the
irradiation allows the determination of the SAR and ILP, while
the highest temperature is given at least after 30 min when an
equilibrium is reached. The values presented in Table S2 in
the ESI† demonstrate that the used LMNVs are superior to
their corresponding controls, which are the plain SPIONs
(SARLMNVs = 1345 W g
−1 vs. SARSPIONs = 678 W g
−1 at 525 kHz
and 20 mT, and SARLMNVs = 1282 W g
−1 vs. SARSPIONs = 611
W g−1 at 750 kHz and 20 mT). The relationship between
Paper Nanoscale
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magnetic hyperthermia and inter-particle interactions/particle
aggregation is a subject of debate, given the contrasting results
found in the literature.29–32 The samples here investigated are
composed of very small magnetic nanoparticles, 3 nm, and the
increased SAR values that the LMNVs present can be attributed
to the fact that these nanoparticles are more stable (as was
demonstrated by the dynamic light scattering studies) and do
not aggregate, as well as to the fact that probably the SPIONs
inside the lipid-based matrix act as a single structure, resulting
into a synergic effect that enhances SAR. It has to be noted
that the SAR values presented in this paper are higher than
those of other studies presented in the literature,33,34 taking
into consideration the experimental conditions. In addition, it
should be emphasized that the fabricated LMNVs have the
ability to increase apoptosis by 50% under a specific treat-
ment, as shown later, and this can be possibly attributed to
the fact that the LMNVs generate a localized intracellular
hyperthermia that results in cell death through apoptotic
mechanisms, as also reported by other groups.35–38 The ILP
values were calculated and reported in Table S2† in order to
make easier the comparison of our system with other systems
in the literature that use different equipment and measures of
the effectiveness of their magnetic-based structures.
Loading and release studies
The percentage of the loaded TMZ (%DL) was found to be
4.1 ± 0.5% (w/w), and was calculated after the extraction of the
drug from the nanovectors using the procedure described in
the ‘Materials and methods’. After calculating the dynamic
loading, we calculated the encapsulation efficiency, %EE =
(weight of the encapsulated TMZ/total weight of TMZ added) ×
100, as well as the yield, %Y = total weight of LMNVs/(total
weight of lipids + Fe3O4 nanoparticles + TMZ), of the loaded
nanovectors, and these percentages were respectively 9.9 ±
2.4% and 17.5 ± 1.0%, percentages which are relatively high
compared to similar nanoparticles in the literature.39,40
Moreover, it should be noted that the LMNVs presented a
pH and an H2O2-dependent release, as well as an enhanced
Fig. 2 Magnetic characterization: (A) magnetization curves of plain SPIONs (red curve) and of LMNVs (green curve) where the saturation magnetiza-
tion can be seen. These curves indicate the superparamagnetic behavior of the LMNVs; (B) magnified images of the hysteresis loops at low magnetic
fields where the coercive field is evident and which proves a better superparamagnetic behavior of the LMNVs, since the coercive field of LMNVs is
lower than that of the 3 nm SPIONs; (C) ZFC–FC curves of the plain SPIONs, where it is evident that the plain SPIONs do not fully express their
superparamagnetic behavior at room temperature, since the two curves are separated at 300 K; (D) response of the LMNVs to an external AMF using
various frequencies and magnetic fields for a concentration of 5.4 mg ml−1. From this graph it is evident that at frequencies between 525 and 752
kHz it is possible to reach the temperature of 43 °C, and that this temperature can be reached in 8.5 min when specific frequencies are used.
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sensitivity to temperature after their exposure to the AMF. The
tested pH, 7.4 and 4.5, were used to simulate normal con-
ditions inside the human body as well as the low pH inside
the lysosomes. With the same rationale, 50 μM of H2O2 was
used in order to simulate the overexpressed amount of reactive
oxygen species (ROS) in the cancerous cells. The data pre-
sented in Fig. 3A and B demonstrate that the LMNVs present a
slow and sustained release of TMZ under physiological con-
ditions (3.3% after 7 days at pH 7.4, black square in Fig. 3A),
and a slight increase in the release when the pH reduces to 4.5
(8.2% after 7 days, black square in Fig. 3B). When H2O2 is
added to the system the release of TMZ does not significantly
change with respect to the samples that were not treated with
H2O2, resulting after 7 days in a release of 1.8% at pH 7.4 and
of 5.0% at pH 4.5, respectively (red circles). These release per-
centages are lower with respect to the corresponding samples
at pH 7.4 (3.3%, black square in Fig. 3A) and 4.5 (8.2%, black
square in Fig. 3B) after 7 days, but this decrement cannot be
considered significant, since only a difference of 2.8% after 7
days is observed between the samples treated at pH 4.5 (8.2%)
and at pH 4.5 + H2O2 50 μM (5.4%), while a difference of 1.9%
was found between the samples at pH 7.4 (3.3%) and at pH 7.4
+ H2O2 50 μM (1.4%). On the other hand, when the samples
are exposed to magnetic hyperthermia an increased release
that reaches 65.8% at pH 7.4 and 63.3% at pH 4.5 can be
observed after 7 days. Even after 4 h, the samples that were
exposed to hyperthermia released the majority of their cargo
(61.0% for pH 7.4 and 57.6% for pH 4.5), demonstrating the
immediate effect of the hyperthermia treatment. It seems that
the increase in temperature affects the release of TMZ, and
this can be attributed to a possible structural deformation of
the lipid matrix when the samples are exposed more than one
time to the AMF. This structural deformation can also be
affected by the pH as well as by the H2O2 that can lead to lipid
peroxidation and degradation of the nanovector. Altogether, it
should be noted that when these three factors (temperature,
pH and H2O2) concur, a synergic effect that results in the com-
plete release of TMZ (100%) after 7 days (Fig. 3B), probably
due to the complete degradation of the LMNVs, can be
observed. On the other hand, when H2O2 and hyperthermia
are applied at pH 7.4 (Fig. 3A), the release (61.3%) after 7 days
is not complete. These results suggest that the fabricated
LMNVs are excellent delivery vehicles that will allow the
release of the encapsulated therapeutics only when a combi-
nation of conditions that can be found only in cancerous
environments will be applied.
Internalization studies
The amount of superparamagnetic nanoparticles associated
with the cells and their specific localization at subcellular level
(internalized into different cell organelles or interfaced to
plasma membrane) affect the efficiency and the apoptotic/
necrotic pathways related to the magnetothermal stimulation.
As an example, magnetothermal heating of lysosomes induces
an increase of the lysosomal ROS and causes caspase-1 depen-
dent cell death.35 The nanoparticle-mediated heating of the
plasma membrane is also able to induce apoptosis by acting at
membrane rafts, activating the damage-associated molecular
pattern (DAMP) and subsequently inducing immunogenic cell
death (ICD).41
For this reason, before performing magnetothermal stimu-
lation, a detailed investigation on the progressive cell uptake
of LMNVs, their association with plasma membranes, and
their internalization in acidic organelles was carried out
(Fig. 4). Fig. 4A shows confocal laser scanning microscopy
(CLSM) imaging of LMNVs (in red), U-87 MG cell membranes
(in green), and nuclei (in blue). Qualitatively, an increase of
LMNV signal was detected at 72 h of nanoparticle incubation
with respect to the 4 h and 24 h time points. Interestingly, the
subcellular localization of LMNVs internalized in cells was
mostly observed in the cortical region of the cells in proximity
of the intracellular side of the plasma membrane, while only a
Fig. 3 Release profile of TMZ at various time points (4, 24, 72, and 168 h) and under various treatments at (A) pH 7.4 and (B) pH 4.5. The presented
values are given as the mean ± standard error of 3 different measurements. LMNVs present a controlled and sustained release profile when pH is 7.4
and 4.5, while their release profile changes when hyperthermia is applied. The combination of pH and H2O2, which is used to simulate the conditions
of ROS excess in cancer cells, does not significantly affect the release of TMZ, but the combination of a low pH, which can be found in lysosomes
(4.5), an increased H2O2 concentration, and hyperthermia leads to 100% release, demonstrating the stimuli-responsive nature of the LMNVs.
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Fig. 4 Investigation of the progressive LMNV uptake by U-87 MG cells: nanovector association with plasma membranes and internalization in acidic
organelles at 4, 24 and 72 h of treatment. (A) Confocal laser scanning microscopy (CLSM) imaging of LMNVs (in red), U-87 MG cell membranes (in
green), and nuclei (in blue); (B) CLSM imaging of LMNVs (in red), acidic organelles (in green), and nuclei (in blue); (C) histograms presenting the area
(%) of plasma membrane signal co-localizing with LMNVs (in blue), of the intracellular region with LMNVs (in red), and of the whole cell (plasma
membrane + intracellular region) without LMNVs (in green); (D) histogram presenting Pearson’s correlation analysis among the signals of LMNVs and
of the acidic organelles. *p < 0.05.
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small amount was found in the perinuclear region, most prob-
ably because of their lipophilic nature.42 The CLSM imaging of
LMNVs that is presented in Fig. 4B (LMNVs in red, acidic orga-
nelles in green, and nuclei in blue) shows a scarce level of
nanomaterial internalization in the acidic compartments at all
the different time points (4, 24, and 72 h). However, an
increased signal co-localization between LMNVs and acidic
organelles was found at 24 h and 72 h of incubation. The
increased LMNV internalization during nanoparticle incu-
bation was also confirmed by flow cytometry (Fig. S6†).
Indeed, a progressively enhanced fluorescence emission of
cells incubated for 0 h (2.1 × 104 ± 0.2 × 103 a.u.), 4 h (16.9 ×
104 ± 2.9 × 103 a.u.), 24 h (60.8 × 104 ± 10.3 × 103 a.u.), and
72 h (77.6 × 104 ± 9.8 × 103 a.u.) with DiO-stained LMNVs was
observed.
The quantitative analyses of LMNV internalization as well
as of their co-localization with the cell membrane and acidic
organelle signals are shown in Fig. 4C and D, respectively. The
histogram in Fig. 4C indicates the area (%) of plasma mem-
brane signal co-localizing with the LMNVs (in blue), of the
intracellular region with LMNVs (in red), and of the whole cell
(plasma membrane + intracellular region) without LMNVs (in
green). As expected, at 72 h of incubation, a significant
increase of the plasma membrane area (7.8 ± 2.0%) and of the
intracellular region (11.2 ± 2.6%) containing LMNVs were
measured with respect to both 4 h (area of plasma membrane
with LMNVs was 1.0 ± 0.1%; intracellular region with LMNVs
was 2.7 ± 0.1%; p < 0.05) and 24 h (area of plasma membrane
with LMNVs was 2.6 ± 0.6%; intracellular region with LMNVs
was 4.4 ± 1.0%; p < 0.05) treatments. At the 72 h time point, a
relatively large amount of the total cell area (plasma mem-
brane + intracellular region) was occupied by LMNVs (19.0 ±
4.5%), compared to the 4 h (3.7 ± 0.2%) and to the 24 h (7.0 ±
1.5%) time points. The histogram presented in Fig. 4D shows
Pearson’s correlation analysis among the signals of LMNVs
and of the acidic organelles. A significant, yet low, increase of
signal co-localization was found just at 72 h (0.116 ± 0.003)
compared to 4 h (0.071 ± 0.008; p < 0.05), thus indicating a
progressive slow internalization of LMNVs in acidic compart-
ments. No significant differences were found at the 24 h inter-
mediate time point (0.130 ± 0.025; p > 0.05) with respect to the
other time points.
Cytotoxicity studies
In order to assess the cytotoxic effect of the fabricated LMNVs,
cell proliferation studies using the WST-1 assay were per-
formed. LMNVs, TMZ-LMNVs and free TMZ that correspond to
the amount loaded in the LMNVs were tested at various con-
centrations (100, 200, 400 and 800 μg ml−1 for the nanovectors
and 2.2, 4.4, 8.75 and 17.5 μg ml−1 for the free TMZ, respect-
ively) and at two time points (24 and 96 h). The results pre-
sented in Fig. S7A† demonstrate that for the first 24 h the
LMNVs do not induce any toxicity even at concentrations up to
800 μg ml−1, while the TMZ-LMNVs cause a reduction of the
metabolic activity, compared to the control, at the highest
used concentration (800 μg ml−1), which nevertheless is not
statistically significant. It has to be noted that the corres-
ponding amounts of free TMZ at 24 h do not induce a
reduction in the metabolic activity of the cells, suggesting that
the toxicity highlighted in cells after a 24 h treatment with
800 μg ml−1 of TMZ-LMNVs can be attributed to an enhanced
TMZ cellular uptake. After 96 h it is evident that the metabolic
activity of cells treated with plain LMNVs is increased com-
pared to the controls, proving the non-toxicity of the fabricated
nanovectors. On the other hand, a reduced increase in the
metabolic activity at 96 h at 400 and 800 μg ml−1 is evident for
the cells treated with TMZ-LMNVs, and this decrease can be
attributed to an enhanced delivery of TMZ inside the cells. A
reduced metabolic activity is finally evident in cells treated
with free TMZ, proving its anti-proliferative ability, which is
enhanced when loaded inside the presented nanovectors as
stated above. Cytotoxicity studies were also performed with
and without the exposure of free TMZ, LMNVs and
TMZ-LMNVs in an alternating magnetic field, and the results
are given in the following paragraph.
Chronic AMF stimulation
The effects of drug-loaded LMNV (TMZ-LMNVs)-assisted mag-
netothermal treatment were investigated on U-87 MG cells after
4 days of AMF treatment (2 h per day) by analyzing the apoptotic
levels with flow cytometry analysis following annexin V-FITC/PI
staining, the expression of the Ki-67 proliferation nuclear
marker and of the p53 tumor suppressor marker (Fig. 5), and
the cell culture metabolism through the WST-1 assay (see ESI,
Fig. S7B†). Eight different experimental conditions were con-
sidered for these experiments: non-treated control cultures
exposed or not to AMF (named “Control + AMF” and “Control”,
respectively), cultures treated with 8.75 µg ml−1 TMZ (amount
corresponding to 400 μg ml−1 of TMZ-LMNVs) and exposed or
not to AMF (named “TMZ + AMF” and “TMZ”, respectively),
LMNV-incubated cultures exposed or not to AMF stimulation
(named “LMNVs + AMF” and “LMNVs”, respectively), and
finally, TMZ-LMNV-treated cultures exposed or not to AMF
stimulation (named “TMZ-LMNVs + AMF” and “TMZ-LMNVs”,
respectively). Fig. 5A shows the flow cytometer scatter plots
(PI vs. annexin V-FITC) and representative confocal images of
the immunostaining of p53 expression (in green), and of
Ki-67 expression (in red) for each experimental condition; in all
fluorescence images nuclei are counter-stained in blue. We
observed that the chronic AMF stimulation was able to affect
the viability and the proliferation levels of U-87 MG cells only
in the presence of LMNVs or TMZ-LMNVs. Indeed, higher
annexin V-FITC fluorescence emissions (apoptotic populations
are highlighted in magenta) in concomitance with a higher
expression of the p53 tumor suppressor marker and lower levels
of the Ki-67 proliferation marker were found in both LMNVs +
AMF and TMZ-LMNVs + AMF, with respect to the other experi-
mental groups. A higher nuclear expression of p53 (prevalently
cytoplasmatic in control cultures) was detected in both
LMNVs + AMF and TMZ-LMNVs + AMF groups compared to
the untreated samples, which was followed by a prominent
decrease of cell number. No relevant differences were found
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Fig. 5 Chronic magnetothermal treatment induces apoptosis, inhibits proliferation, and drastically reduces the U-87 MG cancer cell number. (A)
Flow cytometer scatter plots (propidium iodide vs. annexin V-FITC) and confocal images of p53 expression (in green), Ki-67 expression (in red) and
nuclei (in blue) for untreated cells (CTRL), for cells treated with free TMZ, cells treated with plain LMNVs, and cells treated with TMZ loaded LMNVs
(TMZ-LMNVs), with (+AMF) and without (−AMF) exposure to an alternating magnetic field. Apoptotic populations in the scatter plots are highlighted
in magenta. (B) Histograms reporting the percentage of viable (in black) and annexin V+ apoptotic (in magenta) cells for each experimental condition.
(C) Histogram presenting the percentage of proliferating cells (in green) and of quiescent cells (in orange) following Ki-67 expression evaluation.
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among the Control + AMF and Control groups. This result
reveals the safety of the AMF approach contemplated for the
local stimulation of LMNV-treated cancer cells. Qualitatively, a
small increase of the annexin V+ cells and of p53+ nuclei was
detected in TMZ-LMNVs compared to the control and to the
LMNV experimental groups, probably due to the non-specific
release of TMZ from the drug-loaded vectors. Moreover, a small
increase of annexin V+ cells and of p53+ nuclei was detected in
TMZ-LMNVs, TMZ and TMZ + AMF groups compared to the
Control and to the LMNV experimental groups, thus confirming
the pro-apoptotic effects of the drug.
Quantitative analyses are provided in Fig. 5B and C. In
Fig. 5B the histogram related to the percentage of viable (in
black) and annexin V+ apoptotic (in magenta) cells for each
experimental condition is reported. The percentages of apopto-
tic cells in the entire population that was treated with LMNVs
+ AMF (44.5%) and with TMZ-LMNVs + AMF (50.0%) were sig-
nificantly higher with respect to Control (6.4%), Control + AMF
(0.6%), TMZ (9.4%), TMZ + AMF (10.8%), LMNVs (6.6%) and
TMZ-LMNVs (9.3%) groups (p < 0.05). Single distributions are
reported in ESI, Fig. S8.†
The histogram of Fig. 5C reports the percentage of prolifera-
tive cells (in green) and of quiescent cells (in orange) for each
of the eight experimental groups, evaluated after Ki-67 stain-
ing. The percentage of proliferative cells in LMNVs + AMF
(22.6 ± 1.0%) and in TMZ-LMNVs + AMF (18.2 ± 2.4%) groups
are significantly lower with respect to Control (73.8 ± 1.1%),
Control + AMF (71.3 ± 2.2%), TMZ (64.6 ± 1.9%), TMZ + AMF
(65.9 ± 0.9%), LMNVs (67.9 ± 5.0%) and TMZ-LMNVs (65.75 ±
1.18%) groups (p < 0.05). The best results in terms of apoptotic
and anti-proliferative effects were observed in the TMZ-LMNVs
+ AMF group, thus highlighting the effectiveness of the syner-
gic treatment using magnetothermal stimulation and
chemotherapy.34
Coherently with the smaller number of cells revealed in
TMZ-LMNVs + AMF and LMNVs + AMF treated cultures, ana-
lysis of WST-1 absorbance showed a remarkable (p < 0.005)
decrease of cell metabolism under these two experimental con-
ditions (11.4 ± 0.2% for TMZ-LMNVs + AMF; 15.4 ± 0.3% for
LMNVs + AMF) compared to all the other experimental groups:
Control (100.0 ± 1.9%), Control + AMF (106.1 ± 0.7%), LMNVs
(104.7 ± 1.8%), and TMZ-LMNVs (62.7 ± 3.1%). A small, yet sig-
nificant (p < 0.05), decrease could also be observed after 96 h
between the untreated samples (Control and the Control + AMF)
and samples treated with temozolomide (TMZ, 82.4 ± 3.4%, and
TMZ + AMF, 78.8 ± 7.9%); however these values are still signifi-
cantly higher with respect to those found for the LMNVs + AMF
and TMZ-LMNVs + AMF groups, as reported above.
It is important to highlight that the results acquired from
cell metabolism tests are in agreement with the apoptotic
evaluation, showing better anticancer performances after the
TMZ-LMNVs + AMF combined treatment. Furthermore, cell
metabolism analysis in TMZ-LMNVs samples highlighted a
lower metabolic activity compared to Control, Control + AMF,
and LMNV experimental classes, confirming thus the anti-
cancer effect of TMZ in U-87 MG cells.43
Preliminary analysis of LMNV crossing an in vitro BBB model
The ability of LMNVs to cross an in vitro BBB model was preli-
minarily investigated (Fig. 6), as previously reported in the lit-
erature.44 Briefly, two-compartment BBB models consisting of
porous scaffolds (with pores of 3 µm diameter) were used to
culture brain endothelial cells (BEC) at high confluence. The devel-
oped endothelial layer completely covered the porous scaffold, sep-
arating the luminal chamber (on the top) by the abluminal com-
partment (on the bottom), and was characterized by a sustained
expression of the tight junction marker zonula occludens-1 (ZO-1;
Fig. 6A). The BBBmodel showed a transendothelial electrical resis-
tance (TEER) of 42 Ω cm2 and its permeability to 50 µg ml−1 of
FITC-dextran (4 kDa) was significantly lower with respect to the
plain porous scaffold (without cells; Fig. 6B; p < 0.05).
A progressive crossing of DiO-stained LMNVs through the
BBB was detected when treating the luminal compartment of
the BBB model with 1.3 mg ml−1 of DiO-stained LMNVs
(Fig. 6C), with 7.00 ± 1.82 µg, 22.00 ± 1.40 µg and 52.00 ± 8.96 µg
crossing the abluminal compartment at, respectively, 4, 24 and
48 h of incubation. Fig. 6D shows the fluorescence emission dis-
tributions derived from flow cytometry analysis of U-87 MG cells
seeded in the abluminal compartment at 4, 24, and 48 h of incu-
bation with DiO-stained LMNVs in the luminal chamber. It is
possible to appreciate a progressive shift of the distributions to
higher values of fluorescence emission by increasing the incu-
bation time: the percentage of LMNV+ cells was 0.5%, 3.3% and
16.5% at, respectively, 4, 24 and 48 h of incubation. Fig. 6E
shows representative CLSM imaging of U-87 MG cells (f-actin in
red, nuclei in blue) in the abluminal compartment after 48 h of
incubation with DiO-stained LMNV in the luminal chamber.
These preliminary results concerning the ability of LMNVs
to cross the BBB are certainly promising, and pave the way to
testing the efficiency of the presented nanovectors on more
relevant in vivo GBM models for preclinical evaluations.
Materials and methods
Preparation of lipid-based magnetic nanovectors
25 mg of 1-stearoyl-rac-glycerol (Sigma-Aldrich), 2.5 mg of oleic
acid (Sigma-Aldrich), 2.5 mg of 1,2-dipalmitoyl-rac-glycero-3-
phosphocholine (Sigma-Aldrich), 4 mg of mPEG-DSPE5k
(Sigma-Aldrich), and 2.5 mg of temozolomide (Sigma-Aldrich)
(when TMZ-LMNVs are fabricated), are mixed with 84.5 μl of
an ethanol solution of superparamagnetic iron oxide nano-
particles (15 wt%; US Research Nanomaterials Inc.), inside a
6 ml glass vial. Subsequently, the vial is placed inside an ultra-
sonic bath (Elmasonic S 35w) set at 70 °C in order to melt the
lipids and to allow ethanol to evaporate. After ethanol evapo-
rates, 3 ml of a pre-warmed (70 °C) Tween® 80 (Sigma-Aldrich)
solution (1.0 wt%) were added to the lipid mixture and
immediately sonicated using an ultrasonic homogenizer
(Fisherbrand™ Q125 Sonicator) for 15 min (amplitude 30%,
120 W). After the ultrasonic homogenization, the hot mixture
is transferred to a high pressure homogenizer (HPH, EmulsiFlex-
B15 from Avestin), where the sample is further homogenized by
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passing it 5 times through the homogenizer at a pressure of
100 000 psi. After the homogenization, the LMNVs are placed for
30 min at 4 °C to allow the lipid-based structures to stabilize.
The LMNVs are purified by centrifugation and washing with
ultrapure (Mili-Q) water (3 times for 30 min at 4 °C).
Morphological and physicochemical characterization
Electron microscopy and elemental analysis. The morpho-
logical characterization of the nanovectors was performed in
the high-angle annular dark field-scanning transmission elec-
tron microscopy (HAADF-STEM) imaging mode using an
image-aberration-corrected TEM JEOL JEM-2200FS instrument,
operated at 200 kV. EDS mapping was carried out using a
Bruker XFlash 5060 silicon-drift detector (SDD) with 60 mm2
effective area. For the quantification of the elements, the ana-
lysis was performed using an SEM FEI 200 equipped with a
Bruker Nano XFlash 5010 detector. Sample preparation was per-
formed by casting 20 μl of a concentrated sample on a silicon
substrate and dried on air. Afterwards, the dried sample was
coated with gold and placed under examination, using a voltage
of 20 keV and a current of 83 pA. The quantification of the
elements was performed using Esprit 1.9 software after exclud-
ing the peaks attributed to silicon (Si) and gold (Au).
X-Ray photoelectron spectroscopic analysis. XPS measure-
ments were performed using a Kratos Axis Ultra DLD spectro-
meter using a monochromatized Al Kα source operating at 15
kV and 20 mA. Wide scans were performed at an analyzer pass
energy of 160 eV, while high-resolution narrow scans were per-
formed at a constant pass energy of 10 eV and steps of 0.1 eV.
The photoelectrons were detected at a take-off angle of ϕ = 0°
with respect to the surface normal. The pressure in the ana-
lysis chamber was maintained below 7 × 10−9 Torr for data
acquisition. The data were converted to VAMAS format and
processed using the CasaXPS software, version 2.3.17.
Fig. 6 Ability of LMNVs to cross an in vitro BBB model. (A) Expression of the tight junction marker zonula occludens-1 (ZO-1 in red, nuclei in blue);
(B) crossing of the BBB (with cells; in gray) and of the plain porous scaffold (without cells; in red) of 4 kDa FITC-dextran used as a model substance;
(C) progressive crossing of DiO-stained LMNVs through the BBB model after treating the luminal compartment with 1.3 mg ml−1 of DiO-LMNVs; (D)
fluorescence emission distributions of U-87 MG cells seeded in the abluminal compartment at 4 h, 24 h, and 48 h of incubation with DiO-stained
LMNVs in the luminal chamber, showing the progressive uptake of the DiO LMNVs by the U-87 MG cells; (E) representative CLSM images of U-87
MG cells (f-actin in red, nuclei in blue) in the abluminal compartment after 48 h of incubation with DiO-stained LMNV incubation in the luminal
chamber. *p < 0.05.
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Fourier-transformed infra-red spectroscopy. Attenuated total
reflection Fourier-transformed infra-red spectroscopy
(ATR-FTIR) was performed using a Shimadzu Miracle 10.
Before the measurements, all the samples were freeze-dried
and a small amount of each dried sample was placed on the
diamond surface of the IR cell. The number of scans was set at
45, the scanning range was set at 4000 to 400 cm−1, and the
resolution step at 4 cm−1. The graphs were plotted using
OriginPro software v. 9.1.
Inductively coupled plasma analysis. The ICP elemental ana-
lysis was carried out via inductively coupled plasma optical
emission spectroscopy (ICP-OES) using an iCAP 6300 DUO
ICP-OES spectrometer (Thermo Scientific) operating at an RF
power of 1150 W, using a flush pump rate of 100 rpm, an
auxiliary gas flow rate of 0.5 l min−1 and an analysis pump rate
of 45 rpm. The samples were dissolved overnight in HCl/HNO3
at 3 : 1 (v/v) and diluted with Milli-Q before analysis.
Thermogravimetric analysis (TGA). TGA was performed on
small samples (5 mg) using a Q500 analyzer from TA
Instruments. The scans were performed in the range of
30–600 °C, using a 10 °C min−1 heating rate. Cooling was
achieved using 50 ml min−1 nitrogen flow.
Dynamic light scattering. Dynamic light scattering measure-
ments were performed using a Zeta-sizer NanoZS90 from
Malvern Instruments Ltd. The measurements were carried out
at various temperatures (25, 37, 42 and 46 °C) and in media
with different pH, and conductivity, and different supplements
(H2O, DMEM (Sigma-Aldrich), and DMEM + 10%FBS). For the
hydrodynamic diameter measurements the concentration for
all the samples was adjusted to 100 μg ml−1. The Z-potential
measurements were carried out in ultrapure water at pH 5.5
and the conductivity was adjusted to the range of 30–100
μS cm−1. The attenuation of the samples during measure-
ments was approximately 9. The surface charge measurements
represent the mean ± standard deviation of 3 different
measurements with 17 runs for each of them. Before each
measurement, the samples were sonicated for ∼10 s using a
Bandelin ultrasonic probe at 8 W to avoid the presence of
aggregates.
Magnetic characterization
The magnetic properties of the plain SPIONs as well as of the
LMNVs were measured using a superconducting quantum
interference device (SQUID) from Quantum Design. Hysteresis
loops were measured from −50 to 50 kOe at 5 K and 300 K
upon zero field cooling. The temperature dependence of the
magnetization from 5 to 300 K after zero-field cooling (ZFC)
and after field cooling (FC) was recorded by applying a probe
field of 25 Oe to evaluate the superparamagnetic behavior of
the nanoparticles.
Magnetic hyperthermia. Magnetic hyperthermia was per-
formed using a MagneTherm™ equipment from NanoTherics.
The applied AMF ranged from 12 mT to 20 mT and the
frequencies ranged from 177 kHz to 1017 MHz. The samples
were place inside a 2 ml Nalgene tube, which was inserted
inside a polystyrene case in order to reduce thermal fluctu-
ations. The polystyrene case with the sample was placed inside
a round coil of 9 mm with 44 turns and the hyperthermia
measurements lasted from 30 min to 2 h. For the 2 h time
point, the sample was exposed 2 times, 1 h each, with 1 min of
pause of the AMF between the two exposures.
Evaluation of the specific absorption rate (SAR) and of the
intrinsic loss power (ILP). SAR and ILP values were calculated
for both plain Fe3O4 nanoparticles (3 nm) as well as for the
LMNVs according to eqn (1) and (2). The amount of plain
Fe3O4 nanoparticles that were used was 5.0 mg, while the
amount of the used LMNVs was 5.7 mg (which, according to
TGA, corresponds to 5.0 mg of Fe3O4). Both samples, after
sonication for 5 min using an ultrasonic probe (Fisher
Scientific, 120 W, 90% amplification), were placed at a final
volume of 100 μl inside typical NMR tubes. The tubes were
placed exactly in the center of the coil (9 turn, 44 mm), and
the temperature was recorded every 1 s using an OSENSA
single channel optic fiber. For the calculation of SAR and ILP
values the temperature difference that was used was 6 °C and
corresponded to the difference between 37 °C and 43 °C. The
equations used for the calculation of the above parameters are
given below. For further details see ESI, Table S2.†
SAR ¼ Cp  DcCFe 
dT
dt
ð1Þ
ILP ¼ SAR
f  H2 ð2Þ
Cp is the specific heat capacity of the sample, which in our
case is 4.18 J g−1 K−1; Dc is the density of the colloid at 25 °C,
which is 0.997 g ml−1; CFe is the concentration of the magnetic
moiety in the solvent, dT is the temperature difference (in K) at
the specific measurement time (dt ); dt represents the first 20 s
above 37 °C, where the difference in temperature is measured;
f is the frequency of the magnetic field in Hz and H is the
intensity of the magnetic field in A m−2.
Loading and release studies
The loading and the release studies were performed using an
HPLC Shimadzu LC-20AT similarly to a previously reported
study.45 The chromatographic separation was carried out using
a C-18 column (150 mm × 4.6 mm i.d., 5 μm particle size). The
mobile phase consisted of methanol (Sigma-Aldrich) and water
containing 1% acetic acid of HPLC grade (Sigma-Aldrich) and
pumped in isocratic mode (25% MeOH/70% H2O) with a flow
rate of 0.5 ml min−1. The elution of the analyte was monitored
at 328 nm. In order to calculate the percentages of the encap-
sulated TMZ, as well as the percentages of the cumulative
release from the LMNVs, a standard curve using various con-
centrations of TMZ was prepared. The standard curve was pre-
pared by dissolving 1 mg of TMZ in 1 ml volume of the mobile
phase and filtered using a 0.2 μm syringe filter. A concen-
tration range of 0.1–100 μg ml−1 was prepared upon further
serial dilution. To calculate the loading capacity, 0.25 ml of
methanol (MeOH) were mixed with 2.4 mg of TMZ-loaded
LMNVs and placed under stirring at 70 °C for 3 h. After stir-
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ring, 0.75 ml of cold de-ionized water were added to the MeOH
dispersion and the samples were centrifuged at 15 000 rpm
for 2 h at 4 °C. The supernatant was collected and measured
using the conditions described above. For the release studies,
at each time point the samples were centrifuged at
15 000 rpm for 1 h at 4 °C and the supernatant of each treat-
ment solution was removed and replaced with a fresh one.
80 μl of each supernatant were injected into the HPLC and
analyzed using the parameters described above. Because the
release studies were done in phosphate-buffered saline solu-
tion, the standard curve of TMZ was also prepared in the
same medium. The temozolomide peak was observed at
5.1–5.3 min.
Cell lines
In this study, the glioblastoma multiforme cell line U-87 MG
(ATCC® HTB14™) was used. U-87 MG cells were cultured in
T75 flasks using high glucose DMEM (Sigma-Aldrich) sup-
plemented with 10% FBS (Gibco), 1% penicillin/streptomycin
(Gibco) and 1% L-glutamine (Gibco), under normal culture
conditions (37 °C, 5% CO2, 100% humidity). For all the
experiments the used cells were between passage 10 and
passage 20. The medium during culture was changed every
two days.
Internalization studies
LMNV internalization in living U-87 MG cells was investigated
at different time points (4, 24, and 72 h) through confocal
laser scanning microscopy (CLSM) imaging (C2s system,
Nikon), as previously described,46 and by flow cytometry using
a Beckman Coulter CytoFLEX. Before incubation, LMNVs were
stained with the Vybrant DiD (1,1′-dioctadecyl-3,3,3′,3′-tetra-
methylindodicarbocyanine, 4-chlorobenzene sulfonate salt)
(Thermo Fisher) cell-labeling solution for CLSM, and with
Vybrant DiO (3-octadecyl-2-[3-(3-octadecyl-2(3H)-benzoxazolyl-
idene)-1-propenyl]-, perchlorate) (Thermo Fisher) for flow cyto-
metry experiments. Briefly, 10 mg of LMNVs were incubated
with 5 μl of DiD or DiO for 30 min at room temperature. After
the incubation the nanovectors were centrifuged at 15 000 rpm
for 60 min at 4 °C; the precipitate was collected and re-dis-
persed in distilled sterile water. The procedure was repeated
two times.
Spectral imaging of DiD-stained LMNVs was performed
through CLSM (see ESI, Fig. S9†); Fig. S9A† shows CLSM
images of a single DiD-stained LMNV at different emission
wavelengths and Fig. S9B† reports the corresponding relative
emission spectrum of Fig. S9A,† where the characteristic peak
(λ ∼ 670 nm) of the Vybrant DiD lipophilic dye is evident.
In order to investigate the cell uptake of LMNVs and their
accumulation inside acidic organelles (i.e., lysosomes and late
endosomes), fluorescence staining of the plasma membrane
(CellMask Green Plasma Membrane Stain, 1 : 1000 dilution,
Invitrogen), of the acidic cell compartments (Lysotracker
acidotropic probe, 75 nM, Invitrogen), and of the cell nuclei
(Hoechst 33342, 1 μg ml−1, Invitrogen) was carried out in
serum-free DMEM at 37 °C. Subsequently, the cells were
washed twice with phosphate-buffered saline solution (PBS)
(Sigma-Aldrich) and then rinsed with a phenol red-free com-
plete medium.
Acquisition parameters of the scan area, laser power and
amplification gain were maintained constant for all the
different acquisitions. Finally, images were analyzed by using
the NIS-Elements software (Nikon) through a semi-automatic
approach. Concerning cell uptake, signals of the plasma mem-
branes and of the LMNVs were selected and measured upon
intensity thresholding. The intersection between the two
signals indicated the area of the LMNVs associated with the
plasma membrane. The intracellular area was defined by
selecting the regions of the CLSM image that do not co-localize
with the plasma membrane signal and that contain nuclei.
The intersection between the areas associated with the intra-
cellular region and the LMNVs was then obtained. Co-localiz-
ation analysis between the acidic organelles and the LMNVs
was assessed by investigating Pearson’s correlation parameter
at the different time points.
Flow cytometry of cells incubated with DiO-stained LMNVs
was performed by analyzing the fluorescence emissions (λex =
488 nm; 485 nm < λem < 565 nm) of cells after 0, 4, 24 h and
72 h of nanoparticle treatment. Statistical analysis was per-
formed using ANOVA, followed by a HSD test.
Assessment of cell viability/apoptosis and metabolic activity
The apoptotic effects of the LMNV-assisted magnetothermal
stimulation were investigated using U-87 MG cells after 4 days
of treatment with chronic AMF, using flow cytometry. Samples
treated with free TMZ, LMNVs, TMZ-LMNVs, and untreated
samples were exposed to AMF (20 mT, 750 kHz) for 2 h per day
for 4 days. After 72 h the cells were trypsinized and incubated
with annexin V-FITC/PI (Thermo Fisher) for cell death assess-
ment by flow cytometry. Before flow cytometry the cells were
stained using the following procedure: cells were washed with
Dulbecco’s phosphate-buffered saline solution (DPBS) without
calcium and magnesium and detached using trypsin–EDTA
(0.25%, 5 min at 37 °C). After a centrifugation step (10 min at
3000 rpm), cells were stained with 2.5 μM of annexin V-FITC
and 1 μg ml−1 of propidium iodide (PI) in annexin V binding
buffer (1×) for 15 min at 37 °C protected from light. Cells
stained with annexin V-FITC/PI were evaluated using a
Beckman Coulter CytoFLEX. The percentages of viable and
apoptotic populations were analyzed using the CytoFLEX soft-
ware and subsequently reported on histograms. Untreated
cells were used as controls.
Cell metabolism before and after the chronic magneto-
thermal stimulation was assessed using the WST-1 assay
(Sigma-Aldrich) following a standard protocol described pre-
viously.13 Briefly, cells at pre-determined time points were
incubated with the WST-1 reagent (1 : 10 dilution) for
50 minutes at 37 °C and 5% CO2, and then the supernatant
absorbance at 450 nm was measured using a PerkinElmer
Victor X3 UV-Vis spectrophotometer. The measured absor-
bance values were normalized and expressed as % with respect
to the controls.
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Annexin V-FITC fluorescence emission distributions were
statistically compared by the Kruskal–Wallis test followed by
the Nemenyi–Damico–Wolfe–Dunn post-hoc test; WST-1 data
were analysed using ANOVA followed by the HSD test.
Immunofluorescence staining against p53 and Ki-67 markers
Immunofluorescence staining against the p53 tumor suppres-
sor and the Ki-67 proliferation markers was performed after
4 days of chronic magnetothermal stimulation, similarly to a
previously described study.47 Briefly, after fixing cultures with
4% paraformaldehyde (PFA) in PBS (4 °C, 25 min), cell
membranes were permeabilized with 0.1% Triton X-100
(Sigma-Aldrich) in PBS (room temperature, 25 min), and a
subsequent blocking step with 10% goat serum in PBS (room
temperature, 1 h) was carried out. Cultures were then
incubated with a primary mouse monoclonal anti-p53 anti-
body (1 : 200 dilution, Abcam) or with a primary rabbit IgG
anti-Ki-67 antibody (1 : 150 dilution, Millipore) in 10% goat
serum (37 °C, 45 min), washed 5 times, and finally incubated
with a staining solution composed of a TRITC-conjugated sec-
ondary anti-rabbit antibody (1 : 200; Millipore) or a FITC-conju-
gated secondary anti-mouse antibody (1 : 75; Millipore),
and Hoechst 33342 (1 μg ml−1, Invitrogen) for nucleus
counterstaining.
After washing the cultures 3 times with PBS, imaging was
performed using a CLSM system (C2s system, Nikon) as
described above. Analysis of Ki-67+ nuclei was carried out with
the NIS-Elements software (Nikon) by thresholding and select-
ing the Hoechst and Ki-67 signals by pixel intensity. Statistical
analysis of the collected data was performed with ANOVA, fol-
lowed by the HSD test.
BBB model characterization and LMNV crossing studies
The BBB model was obtained by culturing bEnd.3 cells
(ATCC® CRL-2299™), a well-characterized immortalized
mouse BEC line, at high confluence (seeding density = 8 × 104
cells per cm2) for 5 days on porous inserts of Transwell®
(Corning; average pore diameter of 3 µm) by using the same
cell medium adopted for culturing the U-87 MG cells. The
developed endothelial layer completely covered the porous
scaffold, separating the luminal chamber (on the top) from the
abluminal compartment (on the bottom).
Before performing the LMNV crossing tests, the BBB was
characterized in terms of TEER (assessed with a Millipore
Millicell ERS-2 Volt-Ohmmeter) and permeability to FITC-
dextran (Sigma; molecular weight 4 kDa). Specifically, 100 µl of
a phenol red-free medium containing 50 μg ml−1 of FITC-
dextran were added to the luminal compartments of the BBB
or of the inserts without cells (as controls); the abluminal com-
partments were filled with 600 µl of a phenol red-free medium.
The fluorescence emission of the medium in the abluminal
compartment was measured with a PerkinElmer Victor X3
spectrofluorometer (λex = 488 nm; λem = 520 nm) at different
time points (30 min, 60 min, 4 h, 24 h and 48 h). The values of
fluorescence emission were converted and expressed in terms
of FITC-dextran concentrations using a calibration curve, and
statistically analyzed using ANOVA followed by a HSD test.
The expression of the ZO-1 marker of thigh junctions was
finally verified by immunofluorescence analysis following
treatment with a rabbit IgG primary antibody against ZO-1
(Invitrogen; 1 : 100 dilution in PBS supplemented with 10%
goat serum; 3 h at room temperature) and a goat Alexa Fluor
488-IgG anti-rabbit secondary antibody (Invitrogen; 1 : 200
dilution in PBS supplemented with 10% goat serum; 2 h at
room temperature), following the protocols described for Ki-67
and P53 immunostaining. CLSM was performed by using a
C2s system (Nikon).
Concerning LMNV crossing tests, U-87 MG cells were cul-
tured in the abluminal compartments and 1.3 mg ml−1 of DiO-
stained nanovectors were incubated in the luminal chamber of
the BBB model. At 4, 24 and 48 h of LMNV incubation, the
fluorescence emission of the abluminal medium was
measured and converted to concentration as described above
for the FITC-dextran studies. Moreover, U-87 MG cells were
trypsinized, centrifuged (10 min at 3000 rpm), and the pellet
was resuspended in PBS for flow cytometry analysis (λex =
488 nm; 500 nm < λem < 560 nm; CytoFLEX, Beckman Coulter).
For the CLSM imaging, U-87 MG cells were fixed and treated
with TRITC-conjugated phalloidin (100 μM; Millipore) and
Hoechst 33342 (1 μg ml−1; Invitrogen) for f-actin and nuclei
staining, respectively.
Conclusions
In this work, we have synthesized and characterized lipid-
based magnetic nanovectors (LMNVs) that can be used for
synergic magnetic hyperthermia and chemotherapy against
glioblastoma multiforme. The synthesized LMNVs presented
excellent good SAR values, and were able to increase the temp-
erature of media from 37 °C to 43 °C in approximately 10 min
even when high volumes (1 ml) of the prepared magnetic fluid
were used. In addition, both the LMNVs and the TMZ-LMNVs
demonstrated an increase in terms of apoptotic effects on U-87
MG cells, the TMZ-LMNVs being more effective compared to
the unloaded LMNVs. These lipid nanovectors presented also
a good loading capacity (4.1%) with a sustained release profile
which was found to be stimuli-dependent. Under physiological
conditions the release of TMZ after 7 days was approximately
3.5%, while when low pH, increased H2O2, and magnetic
hyperthermia were simultaneously applied, complete (100%)
release of TMZ was observed. Cell uptake studies showed a pro-
gressive internalization of the nanomaterial that was mostly
located in the cortical area of the cells, and that was associated
with the intracellular side of the plasma membranes with a
partial incorporation into acidic organelles (i.e., lysosomes and
late endosomes). Finally, chronic AFM treatments of U-87 MG
cells incubated with TMZ-loaded LMNVs demonstrated great
anticancer performances, both considering their strong apop-
totic and anti-proliferative activity, resulting in an impressive
reduction of cancer cell population after 4 days of chronic
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stimulation (2 h per day). The strongest anticancer effects were
observed by the application of the magnetothermal stimu-
lation in the presence of the drug-loaded LMNVs, resulting
into enhanced therapeutic effects with respect to samples
treated just with hyperthermia or only with the drug.
The ability of the LMNVs to overcome the BBB limitation
was preliminarily studied using an in vitro BBB model, and the
results showed that after 24 h, almost 40% of the LMNVs
are able to pass and to be thereafter internalized by the
glioblastoma cells.
Future studies will be devoted to the functionalization of
the proposed LMNVs in order to enhance their crossing
through the blood–brain barrier and to facilitate their GBM
delivery by exploiting dual targeting approaches. Finally, the
anticancer efficiency of this multifunctional nanosystem will
be tested on in vivo GBM models.
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